Company profile
enVVeno Medical Corporation
NASDAQ: NVNO · Healthcare · Medical - Devices
#1103 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
40DFH 34DQ 50GM —SS 37
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, filing timeliness · ↓ operating margin, net margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$19.5M
Employees
33
as of 2026-08-27
Market cap
$192.4k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$31.2k$31.2k2019
Net income-$19.5M-$19.5M2025
Operating income-$20.9M-$20.9M2025
Total assets$29.6M$29.6M2025
Liabilities$2.4M$2.4M2025
Equity$27.1M$27.1M2025
Revenue trend
FY2018 – FY2019 · USD
FY18
FY18
FY19
Revenue by segment
Filed disclosures · FY2019
By product
Royalty Income100%
By geography
Not disclosed.
The read
What is enVVeno Medical Corporation’s revenue?
enVVeno Medical Corporation booked $31.2k in FY2019 revenue, contracting 83% year over year — slower than 89% of Healthcare companies we track, at a -62324.4% net margin.
Peers · Healthcare
Cognetivity Neurosciences Ltd.——CuraScientific Corp——Impact BioMedical Inc.32DBioasis Technologies Inc.——UMC, Inc.——Talphera, Inc.47DNeighbors
Orange →Key facts
CEORobert A. Berman
SectorHealthcare
IndustryMedical - Devices
HeadquartersIrvine, CA
ExchangeNASDAQ: NVNO
Employees33
IPO date2018-05-31
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.